Motus GI Holdings Inc (MOTS)
0.07
-0.01
(-7.65%)
USD |
OTCM |
Apr 22, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.3648M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -99.46% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1643 |
| Price to Book Value | 0.1358 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8456 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.97% |
Profile
| Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs, and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy. |
| URL | https://www.motusgi.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 18, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs, and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy. |
| URL | https://www.motusgi.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 18, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |